Stable Clear-Almost Clear Response Is Sustained up to 3 Years in Patients With Moderate-To-Severe Atopic Dermatitis Treated With Lebrikizumab. J of Skin 2025, 9 (6), s599. https://doi.org/10.25251/y4a30r91.